drugset / Trial / NCT00002335

The Safety and Effectiveness of 524W91

NCT00002335

Phase 1 Completed 18 enrolled Glaxo Wellcome
Treatment

Summary

To assess the safety and pharmacokinetics of single oral doses of 524W91 administered in HIV-infected patients. To determine the effects of food on bioavailability of 524W91.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject emtricitabine Other / unclassified Oral